Literature DB >> 15196251

Systemic complement activation following human acute ischaemic stroke.

E D Pedersen1, U Waje-Andreassen, C A Vedeler, G Aamodt, T E Mollnes.   

Abstract

The brain tissue damage after stroke is mediated partly by inflammation induced by ischaemia-reperfusion injury where the complement system plays a pivotal role. In the present study we investigated systemic complement activation and its relation to C-reactive protein (CRP), a known complement activator, and other inflammatory mediators after acute ischaemic stroke. Sequential plasma samples from 11 acute stroke patients were obtained from the time of admittance to hospital and for a follow-up period of 12 months. Nine healthy gender- and age-matched subjects served as controls. The terminal SC5b-9 complement complex (TCC), CRP, soluble adhesion molecules (L-, E- and P- selectin, ICAM, VCAM) and cytokines [tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-8] were analysed. All parameters were within normal values and similar to the controls the first hours after stroke. Terminal complement complex (TCC) increased significantly from 0.54 to 0.74 AU/ml at 72 h (P = 0.032), reached maximum at 7 days (0.90 AU/ml, P < 0.001), was still significantly increased at 12 days (0.70 AU/ml, P = 0.009) and thereafter normalized. CRP increased significantly from 1.02 to 2.11 mg/l at 24 h (P = 0.023), remained significantly increased for 1 week (2.53-2.94 mg/l, P = 0.012-0.017) and thereafter normalized. TCC and C-reactive protein (CRP) correlated significantly (r = 0.36, P < 0.001). The increase in TCC and CRP correlated to the size of infarction (r = 0.80 and P = 0.017 for TCC; r = 0.72 and P = 0.043 for CRP). No significant changes were seen for adhesion molecules and cytokines. In conclusion, transitory systemic complement activation takes place after stroke. The early rise in CRP and the following TCC increase suggest a possible role for CRP in complement activation, which may contribute to inflammation after stroke.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196251      PMCID: PMC1809093          DOI: 10.1111/j.1365-2249.2004.02489.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

1.  Complement in inflammatory tissue damage and disease.

Authors:  Tom E Mollnes; Wen-Chao Song; John D Lambris
Journal:  Trends Immunol       Date:  2002-02       Impact factor: 16.687

Review 2.  Overview: pro-inflammatory cytokines in cerebrovascular ischemia.

Authors:  K Kumar
Journal:  Curr Opin Investig Drugs       Date:  2001-12

3.  Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke.

Authors:  S M Lew; C E Gross; M M Bednar; S J Russell; S P Fuller; C L Ellenberger; D Howard
Journal:  Brain Res Bull       Date:  1999-02       Impact factor: 4.077

4.  Complement depletion improves neurological function in cerebral ischemia.

Authors:  U S Vasthare; F C Barone; H M Sarau; R H Rosenwasser; M DiMartino; W F Young; R F Tuma
Journal:  Brain Res Bull       Date:  1998       Impact factor: 4.077

Review 5.  The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection.

Authors:  A L D'Ambrosio; D J Pinsky; E S Connolly
Journal:  Mol Med       Date:  2001-06       Impact factor: 6.354

Review 6.  The role of inflammation and cytokines in brain injury.

Authors:  B Arvin; L F Neville; F C Barone; G Z Feuerstein
Journal:  Neurosci Biobehav Rev       Date:  1996       Impact factor: 8.989

Review 7.  Molecular mechanisms of cerebral ischemia-induced neuronal death.

Authors:  Sheng T Hou; John P MacManus
Journal:  Int Rev Cytol       Date:  2002

Review 8.  Human C-reactive protein: expression, structure, and function.

Authors:  J E Volanakis
Journal:  Mol Immunol       Date:  2001-08       Impact factor: 4.407

9.  Surface expression of P-selectin on platelets is related with clinical worsening in acute ischemic stroke.

Authors:  Jae-Kwan Cha; Min-Ho Jeong; Eun-Kyung Kim; Yeong-Jin Lim; Byung-Ryp Ha; Sang-Ho Kim; Jae Woo Kim
Journal:  J Korean Med Sci       Date:  2002-12       Impact factor: 2.153

10.  Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement.

Authors:  M R Weiser; J P Williams; F D Moore; L Kobzik; M Ma; H B Hechtman; M C Carroll
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  42 in total

Review 1.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 2.  Complement inhibition as a proposed neuroprotective strategy following cardiac arrest.

Authors:  Brad E Zacharia; Zachary L Hickman; Bartosz T Grobelny; Peter A DeRosa; Andrew F Ducruet; E Sander Connolly
Journal:  Mediators Inflamm       Date:  2010-01-26       Impact factor: 4.711

Review 3.  Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments.

Authors:  Paul M George; Gary K Steinberg
Journal:  Neuron       Date:  2015-07-15       Impact factor: 17.173

4.  Systemic Inflammatory Response Syndrome and Outcomes in Intracerebral Hemorrhage.

Authors:  Amelia K Boehme; Angela N Hays; Kimberly P Kicielinski; Kanika Arora; Niren Kapoor; Michael J Lyerly; Alissa Gadpaille; Harn Shiue; Karen Albright; David Miller; Mitchell S V Elkind; Mark R Harrigan
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

5.  Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.

Authors:  Amy H Kao; Christine A McBurney; Abdus Sattar; Apinya Lertratanakul; Nicole L Wilson; Sarah Rutman; Barbara Paul; Jeannine S Navratil; Andrea Scioscia; Joseph M Ahearn; Susan Manzi
Journal:  Transl Stroke Res       Date:  2013-10-27       Impact factor: 6.829

6.  Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months.

Authors:  Bin Zhang; Ning Yang; Cong Gao
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

7.  Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke.

Authors:  Laure Allard; Natacha Turck; Pierre R Burkhard; Nadia Walter; Anna Rosell; Marianne Gex-Fabry; Denis F Hochstrasser; Joan Montaner; Jean-Charles Sanchez
Journal:  Biomark Insights       Date:  2007-04-19

8.  Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke.

Authors:  Alvaro Cervera; Anna M Planas; Carles Justicia; Xabier Urra; Jens C Jensenius; Ferran Torres; Francisco Lozano; Angel Chamorro
Journal:  PLoS One       Date:  2010-02-03       Impact factor: 3.240

9.  Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes.

Authors:  H M Lee; W Wu; M Wysoczynski; R Liu; E K Zuba-Surma; M Kucia; J Ratajczak; M Z Ratajczak
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

10.  Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'.

Authors:  Titto T Idicula; Jan Brogger; Halvor Naess; Ulrike Waje-Andreassen; Lars Thomassen
Journal:  BMC Neurol       Date:  2009-04-28       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.